Cargando…

Indications and efficacy of canakinumab in Familial Mediterranean Fever: report of three cases

Detalles Bibliográficos
Autores principales:	Tsinti, Maria, Tsitsami, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191431/ http://dx.doi.org/10.1186/1546-0096-12-S1-P253

Ejemplares similares

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

Safe and effective canakinumab-treatment of neonatal onset multisystem inflammatory disease (NOMID)/ chronic infantile neurologic cutaneous and articular (CINCA)
por: Tsinti, M, et al.
Publicado: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Posterior reversible encephalopathy syndrome complicating macrophage activation syndrome in a patient with systemic juvenile idiopathic arthritis
por: Tsinti, Maria, et al.
Publicado: (2014)

Development of focal segmental glomerulosclerosis in a patient with Familial Mediterranean Fever resistant to colchicine therapy under treatment with Canakinumab
por: Barut, K, et al.
Publicado: (2015)

Improvement of Liver Involvement in Familial Mediterranean Fever After the Introduction of Canakinumab: A Case Report
por: Massaro, Maria Grazia, et al.
Publicado: (2020)

Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015)

Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
por: Yücel, Burcu Bozkaya, et al.
Publicado: (2021)

The experience of canakinumab in renal amyloidosis secondary to Familial Mediterranean fever
por: Sozeri, Betul, et al.
Publicado: (2016)

Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023)

Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment
por: Alpa, Mirella, et al.
Publicado: (2015)

Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019)

A Case of Hyperimmunoglobulinemia D Syndrome Successfully Treated with Canakinumab
por: Tsitsami, Elena, et al.
Publicado: (2013)

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
por: Kacar, Mark, et al.
Publicado: (2020)

Challenging case of Familial Mediterranean Fever and its management
por: Al Hosani, A, et al.
Publicado: (2015)

Familial Mediterranean Fever in older children
por: Özdel, Semanur, et al.
Publicado: (2014)

The role of genotype in Familial Mediterranean Fever
por: Özdel, Semanur, et al.
Publicado: (2014)

Comorbidities in patients with Familial Mediterranean Fever
por: Balci-Peynircioğlu, B, et al.
Publicado: (2015)

Neonatal onset Familial Mediterranean Fever
por: Özçakar, ZB, et al.
Publicado: (2015)

Hidradenitis suppurativa and familial Mediterranean fever: a report of 6 cases and literature review
por: Abbara, S, et al.
Publicado: (2015)

The association of Familial Mediterranean Fever and cryptogenic cirrhosis
por: Baskin, E, et al.
Publicado: (2008)

Musculoskeletal complaints in patients with Familial Mediterranean Fever
por: Özçakar, ZB, et al.
Publicado: (2015)

Familial Mediterranean Fever associated diseases in children
por: Özçakar, ZB, et al.
Publicado: (2015)

Articular involvement in childhood Familial Mediterranean Fever
por: Barut, K, et al.
Publicado: (2015)

Quality of life in children with familial Mediterranean fever
por: Öztürk, Ö, et al.
Publicado: (2015)

Familial Mediterranean Fever and Human autoinflammatory diseases
por: Hovhannisyan, L
Publicado: (2015)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever
por: Karabulut, Yusuf, et al.
Publicado: (2022)

Increased frequency of psoriasis in the families of subjects with childhood Familial Mediterranean Fever
por: Barut, Kenan, et al.
Publicado: (2014)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Our successful surgical coronary revascularization in a case with familial Mediterranean fever
por: Yetkin, U, et al.
Publicado: (2013)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

Familial Mediterranean Fever (FMF) and renal disease: first report on 29 Sicilian patients
por: Vitale, A, et al.
Publicado: (2008)

Risk factors for subclinical inflammation in children with familial mediterranean fever
por: Soylu, Alper, et al.
Publicado: (2014)

Evidence based recommendations for genetic diagnosis of Familial Mediterranean Fever
por: Giancane, Gabriella, et al.
Publicado: (2014)

Familial Mediterranean Fever (FMF) before the age of one year
por: Delion, F, et al.
Publicado: (2008)

Screening for inherited metabolic disorders in patients with Familial Mediterranean Fever
por: Kiykim, E, et al.
Publicado: (2015)

L-ficolin and H-ficolin in patients with Familial Mediterranean fever
por: Mkrtchyan, G, et al.
Publicado: (2015)

Effectiveness of Colchicine or Canakinumab in Japanese Patients with Familial Mediterranean Fever: A Single-Center Study
por: Yoshida, Shuhei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8fcs3hm4e7unu7h8m5ml99t6jn